Anti-Integrin Alpha 9 Blockade Suppresses Lymphatic Valve Formation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for lymphatic diseases and transplant rejection are limited, and there is a need for new therapeutic protocols to address lymphatic dysfunction associated with conditions like cancer metastasis, inflammation, and immune disorders.
Innovation Solution
Administering an anti-integrin alpha 9 (Itga-9) therapeutic agent, such as an antibody or RNAi molecule, to suppress lymphatic valve formation and inhibit integrin alpha 9 in lymphatic vessels, thereby preventing or treating corneal valvulogenesis and promoting transplant survival.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for lymphatic diseases and transplant rejection, then existing therapeutic protocols are maintained, but treatment effectiveness is limited and transplant rejection occurs
Solution Approach 1:
The patent extracts and targets a specific molecular mechanism (integrin alpha 9) involved in lymphatic valve formation and transplant rejection. By isolating this specific target and developing antibodies against it, the invention creates a focused therapeutic approach that addresses the root cause of rejection rather than using broad conventional immunosuppression
Solution Approach 2:
The patent introduces anti-integrin alpha 9 antibodies as intermediary therapeutic agents that mediate between the immune system and the transplanted tissue. These antibodies act as intermediaries that specifically block the pathological interactions leading to rejection while preserving necessary immune functions
2Reliability
If lymphatic valve formation is suppressed using anti-Itga-9 therapeutic agents, then transplant survival is promoted, but new therapeutic protocols must be developed and validated
Solution Approach 1:
The patent changes the therapeutic parameter from broad immunosuppression to specific molecular targeting. By shifting the intervention point to integrin alpha 9 blockade, the protocol achieves improved transplant survival through a more precise mechanism, reducing the complexity of managing broad immunosuppressive side effects
Data Source
AI summary
In certain embodiments, the present invention provides methods of suppressing valvulogenesis (VG) in a lymphatic vessel in an inflamed or transplanted tissue or organ in a mammal in need thereof comprising administering an effective amount of an anti-integrin alpha 9 (Itga-9) therapeutic agent to the mammal, and optionally by administering anti-VEGFR-3 agent.